On this page
How much BPC-157 is in the nasal spray?
150 mcg per spray, 30 mg per bottle. BPC-157 nasal spray is a premixed liquid in a metered pump bottle. The amount per spray does not measure how much reaches the bloodstream.1
The product documentation identifies BPC-157 in bacteriostatic water containing 0.9% benzyl alcohol as a preservative.2 Unlike the freeze-dried vial, this format does not require powder reconstitution.
| Detail | Specification |
|---|---|
| Total BPC-157 per bottle | 30 mg = 30,000 mcg |
| Amount per spray | 150 mcg = 0.15 mg |
| Preparation | Premixed liquid; no reconstitution step |
| Actual bottle volume / mL per spray | Not confirmed in the product information reviewed |
| Usable spray count / post-opening expiry | Not established by the available documentation |
A total of 30 mg does not reveal the liquid concentration. Calculating mg/mL also requires the actual fill volume; the size of the bottle in a photograph is not a reliable substitute.
BPC-157 nasal spray: the 30 mg bottle
150 mcg per spray, 30 mg per bottle. Premixed liquid; no reconstitution required.
BPC-157 30 mg Spray
150 mcg per spray, 30 mg per bottle. Premixed liquid; no reconstitution required.
- BPC-157 per bottle
- 30 mg
- BPC-157 per spray
- 150 mcg
- Physical form
- Liquid spray
- Preparation
- Premixed
Ordering is not yet available. Package quantities describe label contents, not an absorbed human dose.
What do one, two or four sprays contain?
One spray contains 150 mcg; two contain 300 mcg; four contain 600 mcg. Count total pump actuations: “one on each side” would mean two sprays in total. This explains the arithmetic, not a therapeutic schedule.
| Illustrative total sprays per day | Total BPC-157 per day | Per week | 4 weeks | 6 weeks | 8 weeks |
|---|---|---|---|---|---|
| 1 | 150 mcg / 0.15 mg | 1.05 mg | 4.2 mg | 6.3 mg | 8.4 mg |
| 2 | 300 mcg / 0.30 mg | 2.10 mg | 8.4 mg | 12.6 mg | 16.8 mg |
| 4 | 600 mcg / 0.60 mg | 4.20 mg | 16.8 mg | 25.2 mg | 33.6 mg |
The formula is sprays × 150 mcg × days ÷ 1,000 = total mg. For example, four sprays per day over 56 days equal 33.6 mg, which exceeds one 30 mg bottle before any losses.
Does 30 mg mean the bottle provides 200 usable sprays?
30,000 ÷ 150 equals 200 nominal spray amounts. It does not verify 200 usable deliveries. Priming, residual liquid and pump performance near the end of a bottle require separate testing. FDA’s nasal-product guidance treats priming and end-of-container delivery as product-specific performance questions.4 A calculated quantity also cannot establish how many days an opened bottle remains usable.
Does the spray need mixing, priming or refrigeration?
It is already mixed and its documented storage temperature is 2–8°C. The original laboratory safety sheet also specifies light protection, upright storage with the cap on, and no freezing.2 Adding extra water would change the concentration and would no longer preserve the original per-spray calculation.
How many times should the pump be primed?
The reviewed BPC-157 documents do not specify an initial priming count, a re-priming count or an interval after which re-priming is required. Obtain the instructions for this exact pump. A number copied from an allergy spray would be an assumption: FDA guidance calls for those characteristics to be established for the finished product.4
What handling instructions are actually documented?
- Keep the bottle upright, capped, refrigerated and protected from light.
- Wipe the nozzle after laboratory handling and do not share devices.
- Avoid spraying toward eyes, the face or other people during laboratory testing.
- Follow the supplied expiry and handling instructions; the public document provides no fixed post-opening use period.
These points come from the product’s laboratory handling sheet, not a validated human-administration protocol.2
Does BPC-157 nasal spray work, and how quickly?
A reliable nasal dose, absorption percentage and time to benefit have not been established in the sources reviewed. FDA’s 2026 assessment found no human pharmacokinetic data for nasal BPC-157. Research using another route cannot supply those missing measurements.3
| Record | Route or question | What it means for this spray |
|---|---|---|
| 1997 rat rhinitis experiment | BPC-157 was given intraperitoneally; capsaicin was put in the nose. | It studied nasal inflammation, not delivery of BPC-157 through a nasal pump.5 |
| PCO-02 trial, NCT02637284 | Registered study of oral BPC-157 tablets. | The registration does not test the nasal format.6 |
| FDA BPC-157 review | Evaluation of clinical, formulation and safety information. | Identifies missing nasal pharmacokinetics and potential immune-response concerns.3 |
The BPC-157 benefits guide explains the tendon, muscle, joint and gut findings. They support research interest in the peptide; they do not demonstrate the same effects from this nasal bottle or establish that it delivers BPC-157 directly to the brain.
What do nasal-spray users report?
In one public discussion of BPC-157/TB-500 nasal blends, a commenter described easier elbow and knee movement after two to three weeks and a return to running, jumping and cycling. The exact composition and strength were not independently confirmed, and this was a different product from the single-ingredient spray featured here.7
The same discussion contains reports of no improvement and nasal dryness. These are individual experiences, not a response-rate estimate. Their spray counts cannot be converted into a protocol for a 150 mcg BPC-only product without knowing the original formulation.
How does nasal spray compare with capsules, a vial or a pen?
| Format | Featured quantity | Preparation or measurement |
|---|---|---|
| Nasal spray | 150 mcg per spray; 30 mg per bottle | Premixed; delivery depends on the finished pump. |
| Capsules | 60 × 500 mcg = 30 mg | Premeasured capsule format. |
| Vial | 10 mg powder | Concentration depends on the final reconstitution volume. |
| Prefilled pen | 15 mg in 3 mL = 5 mg/mL | Already liquid; delivery requires the device calibration. |
The spray and capsule bottle both contain 30 mg by label, but they are not interchangeable treatments. Neither three sprays nor one capsule establishes an equivalent injected amount. The oral-versus-injection guide covers capsules; the dosage and reconstitution guide covers vial concentration and U-100 volume calculations.
What should you check before buying a nasal spray?
Look for the current label, batch identity, total fill volume, amount per actuation, pump instructions and storage period. A peptide-powder certificate and a finished-spray performance report answer different questions.
The available product information describes testing of the peptide lot used to fill the bottle; it does not provide a published finished-spray certificate. The original label and laboratory safety sheet are available here. The vial and capsule COAs elsewhere on this site should not be treated as certificates for this finished spray.
BPC-157 nasal spray questions
Is there a recommended nasal dose or cycle?
No validated regimen is established by the reviewed human evidence. The table above shows labeled quantities at illustrative counts. It does not turn one, two or four sprays into recommended treatment choices.3
Is the bottle definitely 10 mL?
No actual fill volume has been confirmed. The SDS uses a nominal 10 mL assumption for hazard-classification calculations; that is not a product-specific volume statement. Use the current bottle label or a confirmed specification.
What if spraying causes burning, dryness or irritation?
Can I freeze it or keep using a cloudy solution?
The documented instructions say not to freeze the spray and to discard cloudy or discolored solution. They do not provide a way to restore a compromised preparation by shaking, diluting or warming it.2
Does avoiding injections make this format proven safe?
No. FDA specifically identifies potential immune-response concerns for nasal BPC-157 and insufficient human safety information. A nasal presentation does not confer FDA approval. See the side effects and FDA status guide.3
Sources for this nasal-spray guide
- Original BPC-157 spray label.30 mg total and 150 mcg per spray.
- Original spray safety data sheet, PL-SDS-021.Composition, laboratory handling and storage; revision 1.0.
- FDA — BPC-157 compounding advisory committee briefing.2026 evaluation; nasal pharmacokinetics and safety information.
- FDA — nasal-spray product quality guidance.Priming, re-priming, delivered amounts and pump-performance testing.
- Kalogjera et al. — capsaicin-induced rhinitis in rats.European Archives of Oto-Rhino-Laryngology, 1997; BPC-157 was given intraperitoneally.
- NCT02637284 — PCO-02 safety and pharmacokinetics trial.Registered oral-tablet study, not a nasal study.
- Public discussion of BPC-157/TB-500 nasal sprays.Unverified first-person accounts of other products.